Literature DB >> 10100541

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

D O Garrett1, E Jochimsen, K Murfitt, B Hill, S McAllister, P Nelson, R V Spera, R K Sall, F C Tenover, J Johnston, B Zimmer, W R Jarvis.   

Abstract

BACKGROUND: Coagulase-negative staphylococci (CNS) are the major cause of nosocomial bloodstream infection. Emergence of vancomycin resistance among CNS is a serious public health concern, because CNS usually are multidrug-resistant, and glycopeptide antibiotics, among which only vancomycin is available in the United States, are the only remaining effective therapy. In this report, we describe the first bloodstream infection in the United States associated with a Staphylococcus epidermidis strain with decreased susceptibility to vancomycin.
METHODS: We reviewed the hospital's microbiology records for all CNS strains, reviewed the patient's medical and laboratory records, and obtained all available CNS isolates with decreased susceptibility to vancomycin. Blood cultures were processed and CNS isolates identified by using standard methods; antimicrobial susceptibility was determined by using minimum inhibitory concentration (MIC) and disk-diffusion methods. Nares cultures were obtained from exposed healthcare workers (HCWs) to identify possible colonization by CNS with decreased susceptibility to vancomycin.
RESULTS: The bloodstream infection by an S. epidermidis strain with decreased susceptibility to vancomycin occurred in a 49-year-old woman with carcinoma. She had two blood cultures positive for CNS; both isolates were S. epidermidis. Although susceptible to vancomycin by the disk-diffusion method (16-17 mm), the isolates were intermediate by MIC (8-6 microg/mL). The patient had received an extended course of vancomycin therapy; she died of her underlying disease. No HCW was colonized by CNS with decreased susceptibility to vancomycin.
CONCLUSIONS: This is the first report in the United States of bloodstream infection due to S. epidermidis with decreased susceptibility to vancomycin. Contact precautions likely played a role in preventing nosocomial transmission of this strain, and disk-diffusion methods may be inadequate to detect CNS with decreased susceptibility to vancomycin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100541     DOI: 10.1086/501605

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  28 in total

1.  Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.

Authors:  Rodrigo M Paiva; Alice B Mombach Pinheiro Machado; Alexandre P Zavascki; Afonso L Barth
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

2.  In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci.

Authors:  Peter A Smith; Michael E Powers; Tucker C Roberts; Floyd E Romesberg
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Vancomycin and daptomycin pharmacodynamics differ against a site-directed Staphylococcus epidermidis mutant displaying the small-colony-variant phenotype.

Authors:  Marina Wu; Christof von Eiff; Nahed Al Laham; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.

Authors:  S Trakulsomboon; S Danchaivijitr; Y Rongrungruang; C Dhiraputra; W Susaemgrat; T Ito; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 5.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.

Authors:  Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Patrick Caspers; Bérangère Gaucher; Gürkan Mert; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

7.  Emergence of vancomycin-intermediate Staphylococcus aureus and S. sciuri, Greece.

Authors:  Athanassios Tsakris; Ekaterini Papadimitriou; John Douboyas; Fotini Stylianopoulou; Evangelos Manolis
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

8.  Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options.

Authors:  Silvia Natoli; Carla Fontana; Marco Favaro; Alberto Bergamini; Gian Piero Testore; Silvia Minelli; Maria Cristina Bossa; Mauro Casapulla; Giorgia Broglio; Angela Beltrame; Laura Cudillo; Raffaella Cerretti; Francesca Leonardis
Journal:  BMC Infect Dis       Date:  2009-06-04       Impact factor: 3.090

9.  Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.

Authors:  Kristy N Katzenmeyer; Luisa M Szott; James D Bryers
Journal:  Pathog Dis       Date:  2017-08-31       Impact factor: 3.166

10.  Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999.

Authors:  Susan S Huang; Brian J Labus; Michael C Samuel; Dairian T Wan; Arthur L Reingold
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.